Ipamorelin · Updated November 2, 2026

NewsHHS draft peptide policy: ipamorelin is not on the list

What is ipamorelin?

Short answer

Ipamorelin is a lab-made peptide of five amino acids that prompts the pituitary gland to release more of the body’s own growth hormone.^[1] It is not in any FDA-approved drug, and in 2024 FDA’s compounding advisers voted against adding it to the list of substances pharmacies can use.^[1]^[2] Its main human trial, in bowel surgery patients, found no significant benefit over placebo.^[6]

Start your assessment

Your card is only held at checkout. You’re charged only if a provider prescribes.

Licensed provider review
Online, no office visit
Every fact cited to its source

Quick fit check

Tick anything that applies to you. Nothing you tick is saved or sent anywhere.

You have a pituitary problem
FDA says ipamorelin would not be expected to raise growth hormone in people with absent pituitaries or severely damaged growth hormone cells.^[1] Raise this with the provider.
You want a treatment FDA has approved
FDA says there are no FDA-approved drug products containing ipamorelin.^[1] FDA-approved treatments do exist for growth hormone deficiency, such as somatropin.^[1]
You have diabetes or high blood sugar
FDA is concerned that ipamorelin could carry risks like those of approved growth hormone products, including glucose intolerance and diabetes.^[1] Raise this with the provider.
You have or have had cancer
Approved growth hormone product labels warn of an increased risk of tumors, and FDA is concerned similar risks could apply to ipamorelin.^[1] Raise this with the provider.
You compete in a drug-tested sport
The World Anti-Doping Agency’s 2026 list names both ipamorelin and CJC-1295 as prohibited.^[12]

NewsOctober 30, 2026

HHS’s draft peptide policy names six peptides. Ipamorelin is not one of them.

HHS published a notice on October 30, 2026 announcing a draft policy on compounding certain peptides.^[9] Ipamorelin and CJC-1295 are not on its list.^[10]

The list has six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.^[10] For those six, HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound them, as long as every condition in the policy is met.^[10] One condition is a single active ingredient, so blends are left out.^[10]

The policy is not binding on HHS or the public, and comments are due by November 13, 2026 on docket HHS-OASH-2026-0496.^[9] TIME described the moment as “The Peptide Rush Has Begun.”^[11] Ipamorelin’s record is separate: FDA advisers voted against adding it to the compounding list in 2024.^[2]

Ipamorelin: Not among the six peptides the policy names.^[10]
CJC-1295: Also not among the six.^[10]
Blends: Only products with a single active ingredient from the list qualify.^[10]

How to get started

Answer health questions
An online assessment about your health, history and goals.
A licensed provider reviews it
They decide whether a prescription is safe and appropriate for you.
If prescribed, it ships to you
Your card is only held at checkout. You’re charged only if a provider prescribes.

Not ready yet?

Get occasional updates on ipamorelin: new research, safety news and rule changes.

Used only to send these updates. Unsubscribe anytime.

Key facts

What it is: A synthetic peptide of five amino acids that acts as a ghrelin mimetic and growth hormone secretagogue.^[1]
Not to be confused with: Pamorelin, a brand of triptorelin.^[7] Triptorelin is a GnRH analogue used for conditions such as prostate cancer and early puberty.^[8]
FDA status: Not in any FDA-approved drug.^[1] FDA reviewed it and proposed leaving it off the list of substances that can be used in pharmacy compounding.^[1]
Advisory committee: In October 2024, FDA’s compounding advisers voted 0 in favor, 12 against, with 1 abstaining, on each form of ipamorelin.^[2]
Best human trial: A phase 2 trial after bowel surgery found no significant difference from placebo.^[6]
Half-life: About 2 hours when infused into healthy men, with growth hormone peaking at about 40 minutes.^[5]

Ipamorelin’s record so far

When	What happened
1998	Researchers described ipamorelin as a selective growth hormone releaser, based on lab, rat and pig studies.^[4]
1999	A dose-escalation study in healthy men measured how ipamorelin moves through the body and raises growth hormone.^[5]
2014	A phase 2 trial in 114 bowel surgery patients found no significant benefit over placebo.^[6]
September 2023	FDA placed ipamorelin acetate in category 2, its group of bulk substances that may present significant safety risks, for outsourcing facilities.^[3]
October 2024	FDA proposed against listing it, and its advisory committee voted 0 to 12, with 1 abstaining.^[1]^[2]
October 2026	HHS published a draft policy covering six other peptides.^[9]^[10]

How ipamorelin works

It mimics ghrelin: Ipamorelin activates ghrelin receptors, mainly in the hypothalamus, which leads the pituitary to release growth hormone.^[1]
It needs a working pituitary: FDA says ipamorelin would not be expected to raise growth hormone in people with absent pituitaries or severely damaged growth hormone cells.^[1]
It is selective in animals: In pigs, ipamorelin did not raise the stress hormones ACTH and cortisol beyond what the body’s own releasing hormone did, even at very high doses.^[4] FDA also describes it as having no major effect on those hormones.^[1]
It acts in short bursts: In healthy men given an infusion, it caused a single rise in growth hormone that peaked at about 40 minutes and then fell to negligible levels.^[5]

What the evidence shows

Recovery after bowel surgery: In a randomized phase 2 trial, the median time to a first tolerated meal was 25.3 hours on ipamorelin and 32.6 hours on placebo, a difference that was not statistically significant.^[6] The drug was given by IV, and the authors called the study small.^[6]
Growth hormone deficiency: FDA concluded that evidence of effectiveness is limited for any route, with no data supporting the injected-under-the-skin route proposed for compounding.^[1] Professional guidelines do not discuss it for this use.^[1]
Muscle, fat loss, sleep and anti-aging: Clinics market ipamorelin for uses like these.^[1] FDA’s review found no additional data on its effectiveness for other clinical uses.^[1]
With CJC-1295: Clinics market the two together.^[1] A 2026 review reported improved muscle force with the pair in mice with steroid-related muscle loss, and said those findings are limited to animal studies.^[14]

Side effects and safety concerns

In the bowel surgery trial: Low potassium (12.5% vs 3.4% on placebo), insomnia (10.7% vs 5.2%) and high blood sugar at discharge (14.3% vs 8.6%) were more common with ipamorelin.^[1] Across all side effects combined, rates were 87.5% on ipamorelin and 94.8% on placebo.^[6]
Deaths in that trial: Two people given ipamorelin died after developing complications from their colon cancer surgery.^[1] FDA says it is unclear whether the deaths were related to ipamorelin, but that they raise safety concerns.^[1]
Immune reactions: FDA is concerned that injected compounded ipamorelin could trigger immune reactions, because of possible clumping and impurities.^[1]^[3]
Risks tied to growth hormone: FDA is concerned about risks like those on approved growth hormone labels, including tumors, glucose intolerance and diabetes, raised pressure in the skull, fluid retention and pancreatitis.^[1]
Injected use is largely unstudied: FDA found no safety or effectiveness data for the under-the-skin route proposed for compounding.^[1] It says it lacks enough information to know whether the drug would cause harm by certain other injected routes.^[3]
CJC-1295, the other half of the blend: FDA has identified serious adverse events with CJC-1295, including increased heart rate and a whole-body blood vessel widening reaction, and calls clinical data limited.^[3] Two trials in healthy adults reported no serious adverse reactions.^[13]

Common questions

Is ipamorelin the same as Pamorelin?

No. Ipamorelin is a growth hormone peptide.^[1] Pamorelin is an Ipsen brand of triptorelin, a medicine used for conditions such as prostate cancer.^[7]^[8]

Is ipamorelin FDA-approved?

No. FDA says there are no FDA-approved drug products containing ipamorelin.^[1] Its compounding advisers voted against adding it to the 503A bulks list in October 2024, with no votes in favor.^[2]

Can pharmacies compound ipamorelin?

FDA reviewed it and proposed leaving it off the 503A bulks list, and its advisers agreed.^[1]^[2] FDA’s safety-risk page still lists it as a nominated substance that was withdrawn, and as category 2 for outsourcing facilities.^[3] It is also not one of the six peptides in HHS’s draft policy.^[10] Ask any provider or pharmacy how their product is sourced.

Is ipamorelin HGH or a steroid?

Neither. It is a five-amino-acid peptide that stimulates the release of the body’s own growth hormone.^[1]

Does ipamorelin build muscle or burn fat?

Clinics market it that way, but FDA’s review found no additional effectiveness data beyond growth hormone deficiency and post-surgery bowel recovery, and limited evidence for those.^[1]

Why is ipamorelin paired with CJC-1295?

They act on different receptors: ipamorelin on ghrelin receptors, and CJC-1295 as a long-acting analog of growth hormone-releasing hormone.^[1]^[13] A 2026 review said the pair’s muscle findings are limited to animal studies.^[14]

Is ipamorelin banned in sports?

Yes. The World Anti-Doping Agency’s 2026 Prohibited List names it among growth hormone secretagogues, and also lists CJC-1295.^[12]

See if a provider recommends CJC-1295 / ipamorelin

The option offered here is a blend that contains both CJC-1295 and ipamorelin, not ipamorelin alone. It is compounded and not FDA-approved. Complete an online health assessment, and a licensed provider decides whether it or another option is appropriate for you.